Enrique Arvelo

Sevin Rosen Bayless Management Co (Sevin Rosen Bayless) is a venture capital firm founded in 1981. The firm is headquartered in Dallas, Texas.

The International Partnership for Microbicides develops products for the prevention of human immunodeficiency virus. The private company is based in Silver Spring, MD.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

Part of Rothschild & Co. The company is based in New York, NY. Continuation Holdings AG, Rothschild, Inc. provides investment banking and advisory services.

Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge.

Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD.

Columbia MedCom Group, Inc. provides medical communications network services. The company offers pharmaceutical, biotech, device, managed care, and medical association arenas. The company was founded by Jill Rathburn in 1988 and is headquartered in Columbia, MD.

New York Studio School of Drawing Painting & Sculpture provides arts education services. It offers programs and courses where a student gets a certificate and master in fine arts degree. The company was founded on September 23, 1964 and is headquartered in New York, NY.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

CleanSlate Centers, Inc. operates addiction treatment center. It offers drug treatment, alcohol treatment, and treatment for multiple addictions. The company was founded by Amanda Wilson in 2009 and is headquartered in Northampton, MA.

Medscape LLC provides medical information for clinicians and the general public. The company is headquartered in New York, NY.

Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA.

Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA.

Silagene, Inc. provides health care services. The company is headquartered in Hillsborough, NJ.

Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY.

Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA.

Apertor Pharmaceuticals, Inc. manufactures pharmaceutical products.

Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA.

Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation.

Pocket Naloxone Corp. aims to prevent opioid overdose deaths by providing an affordable and accessible OTC naloxone product called Naxswab™ nasal swab. The company is based in Bethesda, MD. The company's vision is to create a world free of opioid overdose deaths, and it has other pipeline assets in development using the same nasal swab applicator delivery platform. The company was founded in 2019 by Behshad Sheldon, Ashanthi Mathai, Kathryn Bowser. Ashanthi Mathai has been the CEO since 2019.

Intergalactic Therapeutics, Inc. is a gene therapy company based in Baltimore, MD. The company is revolutionizing gene therapies with a novel non-viral platform comprised of its versatile synthetic and episomal c3dna molecules. The company uses a customized approach to focal therapeutic delivery using its lead delivery technology, the comet pulsed electric field system, and a proprietary cell-free manufacturing process invented to make gene therapy safer and more accessible for patients. With programs in ophthalmology, oncology, respiratory diseases, and expansion areas including CNS, renal, and musculoskeletal, Intergalactic Therapeutics is dedicated to transforming genetic medicine. The company was founded by Michael D. Ehlers, and Theresa G. H. Heah has been the CEO of the company since 2023.

Adendra Therapeutics Ltd. is an emerging British biotechnology company that was founded in 2021 as a spin-out of the Francis Crick Institute. The company is based in London, UK. The company is focused on discovering and developing new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases, building on new insights into dendritic cell biology. The company was founded in 2021 by Caetano Reis E Sousa, Raj Mehta. Raj Mehta has been the CEO since 2021.

Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation.

Marlinspike Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company operates in the biotechnology industry. The CEO of the company is Raj Chopra.

Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that provides services available through their website. The company is based in New York, NY. The company uses cookies to enhance the user's experience and provide essential website cookies. The CEO of the company is Rajesh Chopra.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.